Breast Cancer
MK1022-016: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
- Details
ClinicalTrials.gov ID:
NCT07060807
Diagnosis Type:
NA
USOR Number:
- Address
,
P: